{
  "ticker": "LLY",
  "target_date": "2025-08-25",
  "actual_date": "2025-08-25",
  "collected_at": "2025-12-08T12:11:09.633449",
  "price": {
    "open": 709.96,
    "high": 712.45,
    "low": 693.21,
    "close": 694.3103637695312,
    "volume": 2898100,
    "change_1d_pct": -2.3,
    "change_7d_pct": 1.82,
    "change_30d_pct": -12.82
  },
  "technicals": {
    "rsi_14": 36.22,
    "sma_20": 703.84,
    "sma_50": 751.25,
    "macd": -16.151,
    "macd_signal": -20.638,
    "macd_histogram": 4.487,
    "bb_upper": 798.18,
    "bb_lower": 609.5,
    "price_vs_sma20_pct": -1.35,
    "price_vs_sma50_pct": -7.58,
    "volume_ratio": 0.41
  },
  "fundamentals": {
    "market_cap": 892359933952,
    "pe_ratio": 48.77168,
    "forward_pe": 43.92895,
    "price_to_book": 37.47854,
    "price_to_sales": 15.017889,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.48,
    "pct_from_52w_low": 59.58
  },
  "macro": {
    "spy": {
      "price": 640.69,
      "change_1d_pct": -0.44,
      "change_7d_pct": -0.15
    },
    "vix": {
      "level": 14.79,
      "signal": "LOW_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.28
    },
    "dollar_index": {
      "level": 98.43
    },
    "gold": {
      "price": 3373.8
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?",
      "source": "Yahoo",
      "datetime": 1756146180,
      "summary": "Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.",
      "url": "https://finnhub.io/api/news?id=f12b7714d439ea56b0fc3578799d56f7a9ab224292d5cb68f7d97af2372a6326"
    },
    {
      "headline": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "source": "MarketWatch",
      "datetime": 1756139460,
      "summary": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=e32ed23490e8099dd1e239d73af9e23190aaa571c48d7a895aa3f32a9ca29ce5"
    },
    {
      "headline": "Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference",
      "source": "Yahoo",
      "datetime": 1756126800,
      "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman, M.D., Lilly chief medical officer will take part in a fireside chat at 9:15",
      "url": "https://finnhub.io/api/news?id=0b614b2a00d287245d0439f6f54778062681432c48c567531ae62ddf7258f1a2"
    },
    {
      "headline": "Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib",
      "source": "Yahoo",
      "datetime": 1756123200,
      "summary": "- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer \u2013 CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cance",
      "url": "https://finnhub.io/api/news?id=f10d74942a2499fcbfcdebd4a95b8253bb4a013b302c11f07a3b6ea7320959f6"
    },
    {
      "headline": "Immuneering Shares Climb On Supply Agreement with Eli Lilly",
      "source": "MarketWatch",
      "datetime": 1756122240,
      "summary": "Immuneering Shares Climb On Supply Agreement with Eli Lilly",
      "url": "https://finnhub.io/api/news?id=e14721313f30525ff5c0d794acf78736398bfe35cfb9bbd5c7ad98e094226625"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "8-K",
      "date": "2025-08-20",
      "description": "d929636d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000119312525184093/d929636d8k.htm"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634987.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000232/xslF345X05/wk-form4_1755634987.xml"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634943.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000230/xslF345X05/wk-form4_1755634943.xml"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634883.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000228/xslF345X05/wk-form4_1755634883.xml"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634822.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000226/xslF345X05/wk-form4_1755634822.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}